InSilico Medicine Cayman TopCo (FRA:O15) Payments of Debt: €0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O15 InSilico Medicine Cayman TopCo FRA:O15
20 GF Score
Price €5.25
! 3 Warning Signs
View Full Analysis

What is InSilico Medicine Cayman TopCo Payments of Debt?

InSilico Medicine Cayman TopCo FRA:O15 +3.96% 20 Payments of Debt is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:O15 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review.

InSilico Medicine Cayman TopCo's Payments of Debt for the six months ended in Dec. 2025 was €0.00 Mil.

InSilico Medicine Cayman TopCo's Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

InSilico Medicine Cayman TopCo Payments of Debt Related Terms

InSilico Medicine Cayman TopCo Payments of Debt Historical Data

* Premium members only.

The historical data trend for InSilico Medicine Cayman TopCo's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InSilico Medicine Cayman TopCo Payments of Debt Chart

InSilico Medicine Cayman TopCo Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Payments of Debt
0.00 0.00 0.00 0.00

InSilico Medicine Cayman TopCo Semi-Annual Data
Dec22 Dec23 Jun24 Dec24 Jun25 Dec25
Payments of Debt Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00
FRA:O15
20GF Score
InSilico Medicine Cayman TopCo FRA:O15
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InSilico Medicine Cayman TopCo Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of €0.00 Mil mean?
InSilico Medicine Cayman TopCo (FRA:O15) has a Payments of Debt of €0.00 Mil as of Dec. 2025. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on InSilico Medicine Cayman TopCo and its competitors.
Is InSilico Medicine Cayman TopCo's Payments of Debt too high?
InSilico Medicine Cayman TopCo's current Payments of Debt is €0.00 Mil. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's Payments of Debt compare to MSFT and ORCL?
InSilico Medicine Cayman TopCo's Payments of Debt of €0.00 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Software company?
A good Payments of Debt depends on the Software industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on InSilico Medicine Cayman TopCo and its competitors. InSilico Medicine Cayman TopCo's current Payments of Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (FRA:O15) has a current Payments of Debt of €0.00 Mil. The current Payments of Debt is €0.00 Mil. InSilico Medicine Cayman TopCo's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (FRA:O15), the current Payments of Debt is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InSilico Medicine Cayman TopCo Business Description

Other Exchanges 03696:Hong Kong
Address Hong Kong Science Park, Unit 310, 3rd Floor, Building 8W, Phase 2, Pak Shek Kok, New Territories, Hong Kong, HKG
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
20GF Score

Get the complete analysis for FRA:O15

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price